Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
AstraZeneca
UBS
Chinese Patent Office
Farmers Insurance
Deloitte
McKinsey
US Army
Queensland Health

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TEMOZOLOMIDE

« Back to Dashboard

Clinical Trials for Temozolomide

Trial ID Title Status Sponsor Phase Summary
NCT00003062 Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage IV non-small cell lung cancer, with or without brain metastases, who have not been treated for metastatic disease with chemotherapy.
NCT00003176 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Unknown status National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide and carmustine in treating patients with anaplastic glioma.
NCT00003176 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Unknown status North American Brain Tumor Consortium Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide and carmustine in treating patients with anaplastic glioma.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Temozolomide

Condition Name

Condition Name for Temozolomide
Intervention Trials
Glioblastoma 139
Glioblastoma Multiforme 101
Brain and Central Nervous System Tumors 89
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Temozolomide
Intervention Trials
Glioblastoma 335
Glioma 154
Central Nervous System Neoplasms 109
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Temozolomide

Trials by Country

Trials by Country for Temozolomide
Location Trials
Canada 223
Australia 99
United Kingdom 86
France 77
Germany 66
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Temozolomide
Location Trials
California 150
Texas 130
New York 122
North Carolina 120
Pennsylvania 116
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Temozolomide

Clinical Trial Phase

Clinical Trial Phase for Temozolomide
Clinical Trial Phase Trials
Phase 4 3
Phase 3 57
Phase 2/Phase 3 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Temozolomide
Clinical Trial Phase Trials
Completed 277
Recruiting 149
Active, not recruiting 107
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Temozolomide

Sponsor Name

Sponsor Name for Temozolomide
Sponsor Trials
National Cancer Institute (NCI) 192
Schering-Plough 36
M.D. Anderson Cancer Center 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Temozolomide
Sponsor Trials
Other 807
Industry 343
NIH 201
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Queensland Health
Chinese Patent Office
Cantor Fitzgerald
AstraZeneca
Citi
Argus Health
Julphar
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.